GlaxoSmithKline Pharmaceuticals share news and announcements
NSE: GLAXOBSE: 500660Pharmaceuticals & BiotechnologyMid Cap
Formerly Glaxo (India)
Last close ₹2,404.70down ₹29.00 (1.19%)BSE ₹2,404.80
Share price at the NSE close on 23 Oct 2026. Previous close ₹2,433.70.
52-week range of traded prices to 23 Oct 2026
₹2,088.10Low, 12 Jun 2026₹3,120.70High, 28 Aug 2026
- Next results date: the board meets on 3 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹40,737 Cr221st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 3 Aug 2026
- 38.1
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 13 May 2026
- 18.0
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 2.37%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 3 Aug 2026
- 50.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 3 Aug 2026
- 56.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 13 May 2026
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 56,17458.6% delivered
GlaxoSmithKline Pharmaceuticals share news and announcements
721 announcements, routine notices left out, newest first. Page 13 of 15.
Jul 2013
22 Jul · Board meeting
Inter-alia, to consider amongst other things, approval of unaudited financial results for the quarter April-June 2013 (Q2) and half-year January-June 2013.
Jun 2013
4 Jun · News Verification
News Verification : The media had reports that GlaxoSmithKline Plc is in the process to increase the stake in GlaxoSmithKline Pharmaceuticals Limited through open offer. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. GlaxoSmithKline Pharmaceuticals Limited has vide its letter inter-alia stated, " The report is speculative in nature and it is the Company's policy not to comment on market speculation."
May 2013
Apr 2013
25 Apr · Board meeting
To consider amongst other things, approval of unaudited financial results for the quarter ended March 31, 2013.2 Apr · Board meeting
To consider and approve re-constitution and adopt the terms of references of the following Sub-Committees of the Board : (1) Audit Committee; (2) Investor Grievance Committee; (3) Remuneration Committee.
Feb 2013
19 Feb · Management
At the Meeting of the Board of Directors of the Company held on February 19, 2013, Ms. Anjali P. Bansal has been appointed as Non-Executive Independent Director with effect from February 19, 2013 in the casual vacancy caused due to resignation of Mr. V. Narayanan.19 Feb · Dividend
Dividend will be payable on April 17, 2013.19 Feb · Corporate action
Company has fixed Book Closure from April 8, 2013 to April 16, 2013 for the purpose of Payment of Dividend19 Feb · Dividend
Board of Directors of the Company at its meeting held on February 19, 2013 has recommended a dividend of Rs. 50/- per equity share (Previous year: Rs 45 per equity share)4 Feb · Board meeting
Inter-alia, to consider amongst other things, approval of audited financial results for the year ended December 31, 2012 and to recommend dividend, if any, on the equity shares of the Company.
Dec 2012
Nov 2012
9 Nov · Retirement of Director
Mr. V Narayanan has retired as a Director of the Company with effect from November 09, 2012.
Oct 2012
18 Oct · Board meeting
To consider amongst other things, approval of unaudited financial results for the quarter ended September 30, 2012.
Aug 2012
17 Aug · Updates
All workmen at Thane Factory (except, one who has retired on July 31, 2012) of the Company have taken Voluntary Retirement Scheme offered by the Company. In view of the above, the Thane Factory has ceased operations. The relevant applications for Closure of the factory are being filed.3 Aug · Retirement of Director
Dr. Ashoke Banerjee has retired as a Alternative Director of the Company with effect from August 1, 2012.1 Aug · Board meeting
Inter-alia, to consider amongst other things, approval of unaudited financial results for the quarter April-June 2012 (Q2) and half-year January-June 2012.
May 2012
Apr 2012
27 Apr · Board meeting
To consider amongst other things, approval of unaudited financial results for the quarter ended March 31, 2012.
Feb 2012
16 Feb · Corporate action
Register of Members & Share Transfer Books of the Company will remain closed from April 02, 2012 to April 10, 2012, (both days inclusive) for the purpose of Payment of Dividend. The dividend will be payable on April 11, 2012.16 Feb · Dividend
Board of Directors of the Company at its meeting held on February 16, 2012 have recommended a dividend of Rs. 45/- per equity share for the year ended December 31, 2011.10 Feb · Board meeting
Inter-alia, to consider amongst other things, approval of audited financial results for the year ended December 31, 2011 and to recommend dividend, if any, on the equity shares of the Company.
Nov 2011
8 Nov · Management
Board of Directors at its Meeting held on November 04, 2011, have appointed Mr. A.N. Roy as Additional Non-Executive Independent Director with effect from November 04, 2011.4 Nov · Results
Standalone Results for the quarter ended on 30-SEP-2011 as follows: Net Sales of Rs. 60756 lacs for quarter ending on 30-SEP-2011 against Rs. 58198 lacs for the quarter ending on 30-SEP-2010. Net Profit / (Loss) of Rs. 14586 lacs for the quarter ending on 30-SEP-2011 against Rs. 15781 lacs for the quarter ending on 30-SEP-2010.
Oct 2011
19 Oct · Board meeting
To consider amongst other things, approval of unaudited financial results for the quarter ended September 30, 2011.
Aug 2011
12 Aug · Management
Following changes in the Directorate with effect from August 01, 2011: (1) Mr. Raju Krishnaswamy has been appointed as an Executive Director- Technical. (2) Mr. Ashoke Banerjee has been appointed as Alternate Director to Mr. Simon Harford.11 Aug · Results
Standalone Results for the quarter ended on 30-JUN-2011 as follows: Net Sales of Rs. 56154 lacs for quarter ending on 30-JUN-2011 against Rs. 49793 lacs for the quarter ending on 30-JUN-2010. Net Profit / (Loss) of Rs. 14754 lacs for the quarter ending on 30-JUN-2011 against Rs. 12899 lacs for the quarter ending on 30-JUN-2010.
Jul 2011
22 Jul · Board meeting
Inter-alia, to consider amongst other things, approval of unaudited financial results for the quarter April-June 2011 (Q2) and half-year January-June 2011.
May 2011
6 May · Results
Standalone Results for the quarter ended on 31-MAR-2011 as follows: Net Sales of Rs. 60290 lacs for quarter ending on 31-MAR-2011 against Rs. 54110 lacs for the quarter ending on 31-MAR-2010. Net Profit / (Loss) of Rs. 46 lacs for the quarter ending on 31-MAR-2011 against Rs. 16119 lacs for the quarter ending on 31-MAR-2010.
Apr 2011
28 Apr · Board meeting
To consider amongst other things, approval of unaudited financial results for the quarter ended March 31, 201113 Apr · Updates
Supreme Court has allowed the Department's appeal and set aside the order of the Delhi High Court, thereby confirming the demand of Rs.71.21 crores raised by the Central Government. The Company is reviewing the contents of the Supreme Court judgment and will take necessary steps as may be legally advised. GlaxoSmithKline is committed to operating with the highest ethical standards and will comply with all applicable legal requirements.
Mar 2011
Feb 2011
14 Feb · Corporate action
Company has fixed the Book Closure Date from March 16, 2011 to March 29, 2011 for the purpose of Payment of Dividend.14 Feb · Results
Standalone Results for the quarter ended on 31-DEC-2010 as follows: Net Sales of Rs. 49063 lacs for quarter ending on 31-DEC-2010 against Rs. 44440 lacs for the quarter ending on 31-DEC-2009. Net Profit / (Loss) of Rs. 11570 lacs for the quarter ending on 31-DEC-2010 against Rs. 10359 lacs for the quarter ending on 31-DEC-2009.14 Feb · Dividend
Board of Directors of the Company at its meeting held on February 14, 2011 have recommended the payment of a Dividend of Rs. 40/- per equity share for the year ended December 31, 2010.14 Feb · Results
Consolidated Results for the year ended on 31-DEC-2010 as follows: Net Sales of Rs. 215105 lacs for year ending on 31-DEC-2010 against Rs. 190777 lacs for the year ending on 31-DEC-2009. Net Profit / (Loss) of Rs. 56057 lacs for the year ending on 31-DEC-2010 against Rs. 50786 lacs for the year ending on 31-DEC-2009.14 Feb · Results
Standalone Results for the year ended on 31-DEC-2010 as follows: Net Sales of Rs. 211164 lacs for year ending on 31-DEC-2010 against Rs. 187077 lacs for the year ending on 31-DEC-2009. Net Profit / (Loss) of Rs. 56369 lacs for the year ending on 31-DEC-2010 against Rs. 51229 lacs for the year ending on 31-DEC-2009.1 Feb · Board meeting
Inter-alia, to consider amongst other things, approval of audited financial results for the year ended December 31, 2010 and to recommend dividend, if any, on the equity shares of the Company.
Jan 2011
5 Jan · Results
The audited results for the year ended 31st December 2010 are expected to be approved by our Board of Director before the end of February 2011 i.e. within a period of two months from the close of the accounting year and as such, we would be announcing the audited financial results within a period of two months of the close of the accounting year. We would therefore like to advice you that as permitted under Clause 41 of the Listing Agreement, we will not be publishing the un-audited financial results for the quarter ended 31st December 2010